Extension of overlap measures for Multi-Class Biomarker Evaluation in Alzheimer's Disease (opens in new tab)

In a progressive disease such as the Alzheimer’s disease (AD), the availability of suitable biomarkers tracking the stages of its progression could markedly accelerate drug development by providing an earlier indication of drug efficacy. Investigators use diagnostic tests to classify disease stages into probable Alzheimer’s disease, mild cognitive impairment (MCI), and normal cognitive aging. In this paper, we focus on developing a proper statistical overlap measure-based method to evaluate t...